With the approval, FDA granted SpringWorks a rare pediatric disease priority review voucher.
Author - David Miller
ADVANCEMENTS IN GLP-1 ANALOG FORMULATION DEVELOPMENT: OVERCOMING...
Obesity is a significant global health challenge that requires lifestyle changes and effective...
Axplora Announces €50 Million Investment in GLP-1...
This site was previously the beneficiary of a €7.3 million (US$7.6 million) investment, made in...
Drug Digest: Advances in Small-Molecule Manufacturing
In this exclusive Drug Digest video interview Anil Kane from Thermo Fisher Scientific will be...
MMS Acquires Exploristics and Its Flagship Modeling and...
In seeking a data-driven approach to efficient drug development, MMS aims to enhance its...
Navigating Drug Development: The Critical Role of Performing...
International Day of Women and Girls in Science 2025: Inspiring...
Pharmaceutical Technology® spoke with Sabine Gölden, eLearning & Training Lead at MAIN5, about...
FDA Approves Bavarian Nordic’s Chikungunya Vaccine Vimkunya
Vimkunya is the first FDA-approved vaccine for chikungunya in patients over 12 years of age.
How Abpro Plans to Leverage the Public Markets
In this part of his Pharmaceutical Executive video interview, Ian Chan, CEO of Abpro talks about...
International Day of Women and Girls in Science: Fostering STEM...
Agnes Cwienczek, director of Product Management at ArisGlobal, talks with Pharmaceutical...